A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2001
10/18/2001	CA2405104A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405083A1 New bromodomain protein
10/18/2001	CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001	CA2405052A1 Chlamydial glycolipid vaccines
10/18/2001	CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2403365A1 Quinazoline compounds
10/18/2001	CA2403012A1 Chemical compounds
10/18/2001	CA2372352A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/17/2001	EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001	EP1145718A1 DICARBA-closo-DODECABORANE DERIVATIVES
10/17/2001	EP1145001A2 (in vitro) model for gastrointestinal inflammation
10/17/2001	EP1144690A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144650A2 Goodpasture antigen binding protein
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144634A2 Novel complex-forming proteins
10/17/2001	EP1144633A1 Polypeptide
10/17/2001	EP1144630A2 Human cell signaling proteins (csig)
10/17/2001	EP1144625A2 Nucleic-acid binding proteins
10/17/2001	EP1144617A2 Cancer-associated proteins
10/17/2001	EP1144614A2 33 human secreted proteins
10/17/2001	EP1144602A1 Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same
10/17/2001	EP1144600A2 Akt-3 nucleic acids, polypeptides, and uses thereof
10/17/2001	EP1144598A2 Human homologues of proteins regulated by circadian rhythms
10/17/2001	EP1144454A2 Modified peptides as therapeutic agents
10/17/2001	EP1144443A2 Human membrane transport proteins
10/17/2001	EP1144431A2 16-hydroxyestratrienes as selective estrogens
10/17/2001	EP1144425A1 Derivatives of monosaccharides as cell adhesion inhibitors
10/17/2001	EP1144412A1 Immunosuppressive effects of pteridine derivatives
10/17/2001	EP1144411A1 Antihistaminic spiro compounds
10/17/2001	EP1144409A2 Phenyl urea and phenyl thiourea derivatives
10/17/2001	EP1144394A1 1-heterocycle substituted diarylamines
10/17/2001	EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor
10/17/2001	EP1144390A2 Kinase inhibitors
10/17/2001	EP1144388A1 Acyl derivatives which treat vla-4 related disorders
10/17/2001	EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
10/17/2001	EP1144385A1 Benzoheterocycles and their use as mek inhibitors
10/17/2001	EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
10/17/2001	EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors
10/17/2001	EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/17/2001	EP1144368A2 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
10/17/2001	EP1144365A2 Inhibitors of alpha-4 beta-1 mediated cell adhesion
10/17/2001	EP1144362A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
10/17/2001	EP1144305A1 NOVEL sPLA 2 INHIBITORS
10/17/2001	EP1144008A1 Modulation of systemic memory t cell trafficking
10/17/2001	EP1143994A2 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
10/17/2001	EP1143993A1 Method of suppressing ongoing acute allograff rejection
10/17/2001	EP1143985A2 Use of lactobacillus salivarius
10/17/2001	EP1143984A1 Egg anti-inflammatory composition and method of treating and preventing inflammation
10/17/2001	EP1143965A1 Carbocyclic potassium channel inhibitors
10/17/2001	EP1143946A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
10/17/2001	EP1143942A2 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases
10/17/2001	EP1143933A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
10/17/2001	EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers
10/17/2001	EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
10/17/2001	EP1064291A4 Methods of synthesizing gm3
10/17/2001	EP1001955B1 1,2,4-triazolo 4,3-b]pyrido 3,2-d]pyridazine derivatives and pharmaceutical compositions containing them
10/17/2001	EP0833818B1 3-acylindoles as cb2 receptor agonists
10/17/2001	EP0717632B1 A food additive for improving immunity
10/17/2001	CN1318056A Pyridinum derivatives for management of aging-related and diabetic vascular complications, process for their prepn. and therepeutic uses thereof
10/17/2001	CN1318054A Novel compounds
10/17/2001	CN1317976A Multicomponent vaccines
10/17/2001	CN1317975A Method of using zot or zonulin to inhibit lymphocyte proliferation in antigen-specific manner
10/17/2001	CN1317965A Compounds having IgE affecting properties
10/17/2001	CN1317569A Method for preparing mammal cell kinetin synthetic inhibitory factor
10/17/2001	CN1317495A Ocean thalassiomycete hypoxylon polyose and its extracting process and application
10/17/2001	CN1317343A Pharmaceutical Application of mammal cell kinetin synthetic inhibitory factor
10/17/2001	CN1317342A Eye preparation
10/17/2001	CN1317324A Oral liquid for warming lung and dispelling cold and its preparing process
10/17/2001	CN1072956C Health oral liquid and its prepn. method
10/17/2001	CN1072955C Tonic liquid of black ewe's placenta extract and its preparing method
10/16/2001	US6303789 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
10/16/2001	US6303774 Antiviral agents, anticancer agents, metabolic moderators
10/16/2001	US6303754 Recombinant procvf
10/16/2001	US6303659 Administering adamantane derivative for therapy of rheumatoid arthritis
10/16/2001	US6303637 For therapy of autoimmune disease, prophylaxis of resistance to transplantation or transplantation rejection of organs or tissues; suppressing immune system
10/16/2001	US6303601 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
10/16/2001	US6303600 Substituted azabicyclic compounds
10/16/2001	US6303577 Use of a peptide compound in the treatment of systemic lupus erythematosus
10/16/2001	US6303572 Control of acidic gut syndrome
10/16/2001	US6303571 To screen for antibacterial compounds; genetic immunization; therapy and prophylaxis
10/16/2001	US6303374 By hybridization with nucleic acid; controlling apoptosis and programmed cell death; alzheimers, parkinsons, autoimmune, and viral diseases; cancer; amyotrophic lateral sclerosis
10/16/2001	US6303347 Vaccines
10/16/2001	US6303334 Nucleotide sequences coding polypeptides for use in as a viricide and in gene therapy
10/16/2001	US6303333 Expression vector which codes polypeptides for the diagnosis and treatment of cancer, dietetics, inflammation, cardiovascular disorders, crohn's diseases, neuropathies and immune defects
10/16/2001	US6303314 T-cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
10/16/2001	US6303292 Geneticlly engineered viral polypeptides; for use in diagnosis and treatment of viral infection
10/16/2001	US6303151 Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
10/16/2001	US6303121 Method of using human receptor protein 4-1BB
10/16/2001	US6303114 IL-12 enhancement of immune responses to T-independent antigens
10/16/2001	CA2036977C Imidazopyridazines, their production and use
10/16/2001	CA2015470C Fluorinated arachidonic acid derivatives
10/12/2001	CA2335109A1 Cxcr4 agonist treatment of hematopoietic cells
10/12/2001	CA2322368A1 Animal model for allergic disorders
10/11/2001	WO2001075110A2 Mucin-1 specific binding members and methods of use thereof
10/11/2001	WO2001075109A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
10/11/2001	WO2001075074A1 Novel proteins

1 ... 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 ... 1172